Related references
Note: Only part of the references are listed.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
Eva Schrezenmeier et al.
NATURE REVIEWS RHEUMATOLOGY (2020)
Response to the editorial COVID-19 in patients with cardiovascular diseases. Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes
Christian Funck-Brentano et al.
ARCHIVES OF CARDIOVASCULAR DISEASES (2020)
Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin An Analysis of the World Health Organization Pharmacovigilance Database
Lee S. Nguyen et al.
CIRCULATION (2020)
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Xueting Yao et al.
CLINICAL INFECTIOUS DISEASES (2020)
Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing
Maria Garcia-Cremades et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report
C. -Y. Xu et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2020)
Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data
Aurelie Grandvuillemin et al.
THERAPIE (2020)
Off-label use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers
Alexandre Gerard et al.
THERAPIE (2020)
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)
Nicholas J. Mercuro et al.
JAMA CARDIOLOGY (2020)
Potential Effects of Coronaviruses on the Cardiovascular System A Review
Mohammad Madjid et al.
JAMA CARDIOLOGY (2020)
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin
Ehud Chorin et al.
NATURE MEDICINE (2020)
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Antonis Fanouriakis et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Hydroxychloroquine - How Much Is Too Much?
Vaneet Kaur Sandhu et al.
JOURNAL OF RHEUMATOLOGY (2019)
Toxicokinetics of hydroxychloroquine following a massive overdose
Jonathan de Olano et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2019)
Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered?
Konstantinos Tselios et al.
JOURNAL OF RHEUMATOLOGY (2019)
Antimalarial-induced cardiomyopathy: a systematic review of the literature
K. Tselios et al.
LUPUS (2018)
Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature
Clotilde Chatre et al.
DRUG SAFETY (2018)
Determination and Interpretation of the QT Interval: Comprehensive Analysis of a Large Cohort of Long QT Syndrome Patients and Controls
Arja Suzanne Vink et al.
CIRCULATION (2018)
Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential
Rebecca A. Capel et al.
HEART RHYTHM (2015)
Hydroxychloroquine-Induced Cardiomyopathy: Case Report, Pathophysiology, Diagnosis, and Treatment
Haran Yogasundaram et al.
CANADIAN JOURNAL OF CARDIOLOGY (2014)
The Risk of Toxic Retinopathy in Patients on Long-term Hydroxychloroquine Therapy
Ronald B. Melles et al.
JAMA OPHTHALMOLOGY (2014)
Chloroquine cardiomyopathy - a review of the literature
Ernst Toennesmann et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2013)
The Impact of Duration of Treatment on Reported Time-to-Onset in Spontaneous Reporting Systems for Pharmacovigilance
Ghazaleh Karimi et al.
PLOS ONE (2013)
Inhibition of cardiomyocyte lysosomal activity in hydroxychloroquine cardiomyopathy
Andrea Frustaci et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2012)
Evidence for risk of cardiomyopathy with hydroxychloroquine
M. D. Sumpter et al.
LUPUS (2012)
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review
G. Ruiz-Irastorza et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Prevention of Torsade de Pointes in Hospital Settings A Scientific Statement From the American Heart Association and the American College of Cardiology Foundation
Barbara J. Drew et al.
CIRCULATION (2010)
Chloroquine cardiotoxicity in long-term lupus therapy in two patients
A. Saussine et al.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE (2009)
AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram Part IV: The ST Segment, T and U Waves, and the QT Interval A Scientific Statement From the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society Endorsed by the International Society for Computerized Electrocardiology
Pentti M. Rautaharju et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Cardiotoxicity of antimalarial drugs
Nicholas J. White
LANCET INFECTIOUS DISEASES (2007)
Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers
ER Smith et al.
JOURNAL OF EMERGENCY MEDICINE (2005)
Assessment of prolonged QT and JT intervals in ventricular conduction defects
PM Rautaharju et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
Infectious complications in SLE after immunosuppressive therapies
I Kang et al.
CURRENT OPINION IN RHEUMATOLOGY (2003)
Cardiovascular toxicities of immunosuppressive agents
LW Miller
AMERICAN JOURNAL OF TRANSPLANTATION (2002)
Share Paper
